Status:
UNKNOWN
Stability of Biometry in Meibomian Gland Dysfunction
Lead Sponsor:
Vienna Institute for Research in Ocular Surgery
Conditions:
Meibomian Gland Dysfunction
Eligibility:
All Genders
21-99 years
Phase:
NA
Brief Summary
Accurate biometry is an essential and indispensable tool in preoperative cataract surgery setting to yield optimal postoperative refractive outcome. However, some recent studies indicate that preopera...
Detailed Description
Accurate biometry is an essential and indispensable tool in preoperative cataract surgery setting to yield optimal postoperative refractive outcome. 31 Patients suffering from DED caused by MGD will b...
Eligibility Criteria
Inclusion
- Age older than 18 years
- Evidence of meibomian gland dysfunction
- Meibomian gland secretion score equal or less than 15 (for 15 glands of the lower eye lid) using the meibomian gland evaluator (see below)
Exclusion
- Usage of eye drops other than lubricants (e.g. antibiotics, steroids, cyclosporin-A)
- Usage of systemic antibiotic therapy
- Any pathology of the ocular surface except dry eye disease (e.g. corneal scarring, cornea ectasia)
- Ocular surgery within prior 3 months
- Ocular injury within prior 3 months
- Ocular herpes of eye or eyelid within prior 3 months
- Active ocular infection
- Active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months
- Eyelid abnormalities that affect lid function
- Ocular surface abnormality that may compromise corneal integrity
- Pregnancy
Key Trial Info
Start Date :
February 6 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2023
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT04322656
Start Date
February 6 2020
End Date
September 30 2023
Last Update
October 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vienna Institute for Research in Ocular Surgery
Vienna, Austria